SEQUENCE LISTING

<110> Revance Therapeutics, Inc.

<120> METHODS OF AND COMPOSITIONS FOR TREATMENT OF UPPER LIMB SPASTICITY

<130> 13720.0035P1

<140> PCT/US22/17170
<141> 2022-02-21

<150> 63/151,795
<151> 2021-02-21

<160> 10

<170> PatentIn version 3.5

<210> 1
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<220>
<221> misc
<222> (1)..(20)
<223> Gly at positions 1-20 can be present or absent

<220>
<221> misc
<222> (32)..(51)
<223> Gly at positions 32-51 can be present or absent

<400> 1

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly Gly Gly
    50

<210> 2
<211> 51
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<220>
<221> MISC
<222> (1)..(20)
<223> Gly can be present or absent

<220>
<221> MISC
<222> (32)..(51)
<223> Gly can be present or absent

<400> 2

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly
            20   25   30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
        35   40   45

Gly Gly Gly
    50

<210> 3
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<220>
<221> misc
<222> (1)..(20)
<223> Gly can be present or absent

<220>
<221> misc
<222> (30)..(49)
<223> Gly can be present or absent

<400> 3

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
20 25 30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
35 40 45

Gly

<210> 4
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<400> 4

Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Lys Lys Arg Arg Gln
20 25 30

Arg Arg Arg
35

<210> 5

<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<220>
<221> MISC
<222> (1)..(20)
<223> Gly is present or absent

<220>
<221> MISC
<222> (26)..(45)
<223> Arg is present or absent

<400> 5

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1 5 10 15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
20 25 30

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
35 40 45

<210> 6
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; Antennapedia PTD

<400> 6

Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp
1 5 10 15

Lys Lys Cys

<210> 7

<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; positively charged carrier

<400> 7

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Tyr Gly Arg Lys
20 25 30

Lys Arg Arg Gln Arg Arg Arg
35

<210> 8
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<400> 8

Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Gly Arg Asp
20 25 30

Asp Arg Arg Gln Arg Arg Arg
35

<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; polylysine polypeptide

<220>
<221> misc
<222> (11)..(20)
<223> Lys is either present or absent

<400> 9

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys
20

<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> synthetic construct; protein transduction domain

<400> 10

Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg
1 5 10